In an exclusive global licensing and development deal, Astellas Pharma Inc. is building on a single vaccine deal it struck with Immunomic Therapeutics Inc. (ITI) earlier this year to capture rights to ITI's full portfolio of allergy-focused DNA vaccines. The agreement carries $300 million for ITI up front plus 10 percent royalties of net sales of the potential products while leaving ITI with all rights to additional applications of the company's lysosomal associated membrane protein vaccine, or LAMP-vax, technology.